Literature DB >> 34644398

Humour-based interventions for people with schizophrenia.

Yasushi Tsujimoto1,2,3, Yuri Nakamura4, Masahiro Banno3,5,6, Kunihiro Kohmura5,6, Hiraku Tsujimoto7, Yuki Kataoka3,8,9,10.   

Abstract

BACKGROUND: Humour-based interventions are defined as any intervention that promotes health and wellness by stimulating a playful discovery, expression, or appreciation of the absurdity or incongruity of life's situations. Humour-based interventions can be implemented in different settings, including hospitals, nursing homes and day care centres. They have been posed as an adjunct to usual care for people with schizophrenia, but a summary of the evidence is lacking.
OBJECTIVES: To examine the effects of humour-based interventions as an add-on intervention to standard care for people with schizophrenia. SEARCH
METHODS: On 31 July 2019 and 10 February 2021 we searched the Cochrane Schizophrenia Group's study-based register of trials, which is based on CENTRAL, CINAHL, ClinicalTrials.Gov, Embase, ISRCTN, MEDLINE, PsycINFO, PubMed, and WHO ICTRP. SELECTION CRITERIA: We included all randomised controlled trials comparing humour-based interventions with active controls, other psychological interventions, or standard care for people with schizophrenia. We excluded studies fulfilling our prespecified selection criteria but without useable data from further quantitative synthesis. DATA COLLECTION AND ANALYSIS: Two review authors independently inspected citations, selected studies, extracted data and appraised study quality, following the guidance from the Cochrane Handbook for Systematic Reviews of Interventions. For binary outcomes we calculated risk ratios (RRs) and their 95% confidence intervals (CIs). For continuous outcomes we calculated the mean differences (MDs) and their 95% CIs. We assessed risks of bias for included studies and created summary of findings tables using the GRADE approach. MAIN
RESULTS: We included three studies in this review for qualitative synthesis, although one study did not report any relevant outcomes. We therefore include two studies (n = 96) in our quantitative synthesis. No data were available on the following prespecified primary outcomes: clinically-important change in general mental state, clinically-important change in negative symptoms, clinically-important change in overall quality of life, and adverse effects. As compared with active control, humour-based interventions may not improve the average endpoint score of a general mental state scale (Positive and Negative Syndrome Scale (PANSS) total score: MD -1.70, 95% CI -17.01 to 13.61; 1 study, 30 participants; very low certainty of evidence); positive symptoms (PANSS positive symptom score: MD 0.00, 95% CI -2.58 to 2.58; 1 study, 30 participants; low certainty of evidence), negative symptoms (PANSS negative symptom score: MD -0.70, 95% CI -4.22 to 2.82; 1 study, 30 participants; very low certainty of evidence) and anxiety (State-Trait Anxiety Inventory (STAI): MD -2.60, 95% CI -5.76 to 0.56; 1 study, 30 participants; low certainty of evidence). Due to the small sample size, we remain uncertain about the effect of humour-based interventions on leaving the study early as compared with active control (no event, 1 study, 30 participants; very low certainty of evidence). On the other hand, humour-based interventions may reduce depressive symptoms (Beck Depression Inventory (BDI): MD -6.20, 95% CI -12.08 to -0.32; 1 study, 30 participants; low certainty of evidence). Compared with standard care, humour-based interventions may not improve  depressive symptoms (BDI second edition: MD 0.80, 95% CI -2.64 to 4.24; 1 study, 59 participants; low certainty of evidence). We are uncertain about the effect of humour-based interventions on leaving the study early for any reason compared with standard care (risk ratio 0.38, 95% CI 0.08 to 1.80; 1 study, 66 participants; very low certainty of evidence). AUTHORS'
CONCLUSIONS: We are currently uncertain whether the evidence supports the use of humour-based interventions in people with schizophrenia. Future research with rigorous and transparent methodology investigating clinically important outcomes is warranted.
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2021        PMID: 34644398      PMCID: PMC8514248          DOI: 10.1002/14651858.CD013367.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  93 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

2.  Issues in the meta-analysis of cluster randomized trials.

Authors:  Allan Donner; Neil Klar
Journal:  Stat Med       Date:  2002-10-15       Impact factor: 2.373

3.  Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins.

Authors:  D R Weinberger; K F Berman; R Suddath; E F Torrey
Journal:  Am J Psychiatry       Date:  1992-07       Impact factor: 18.112

Review 4.  Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology.

Authors:  Andrew C Leon; Craig H Mallinckrodt; Christy Chuang-Stein; Donald G Archibald; Graeme E Archer; Kevin Chartier
Journal:  Biol Psychiatry       Date:  2006-02-28       Impact factor: 13.382

5.  Cognitive-behavioural therapy for persistent and recurrent psychosis in people with schizophrenia-spectrum disorder: cost-effectiveness analysis.

Authors:  Mark van der Gaag; A Dennis Stant; Kerstin J K Wolters; Erik Buskens; Durk Wiersma
Journal:  Br J Psychiatry       Date:  2011-01       Impact factor: 9.319

6.  [Humor therapy in the depressed elderly: results of an empirical study].

Authors:  R D Hirsch; K Junglas; B Konradt; M F Jonitz
Journal:  Z Gerontol Geriatr       Date:  2010-02       Impact factor: 1.281

7.  [The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use].

Authors:  J P Boissel; M Cucherat; W Li; G Chatellier; F Gueyffier; M Buyse; F Boutitie; P Nony; M Haugh; G Mignot
Journal:  Therapie       Date:  1999 Jul Aug       Impact factor: 2.070

8.  Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia.

Authors:  Alessandro Bertolino; Grazia Caforio; Giuseppe Blasi; Mariapia De Candia; Valeria Latorre; Vittoria Petruzzella; Mario Altamura; Gaetano Nappi; Sergio Papa; Joseph H Callicott; Venkata S Mattay; Antonello Bellomo; Tommaso Scarabino; Daniel R Weinberger; Marcello Nardini
Journal:  Am J Psychiatry       Date:  2004-10       Impact factor: 18.112

9.  Imputation of response rates from means and standard deviations in schizophrenia.

Authors:  Myrto T Samara; Loukia M Spineli; Toshi A Furukawa; Rolf R Engel; John M Davis; Georgia Salanti; Stefan Leucht
Journal:  Schizophr Res       Date:  2013-11-18       Impact factor: 4.939

Review 10.  Yoga versus standard care for schizophrenia.

Authors:  Julie Broderick; Abigail Knowles; Jonathan Chadwick; Davy Vancampfort
Journal:  Cochrane Database Syst Rev       Date:  2015-10-21
View more
  1 in total

Review 1.  Humour-based interventions for people with schizophrenia.

Authors:  Yasushi Tsujimoto; Yuri Nakamura; Masahiro Banno; Kunihiro Kohmura; Hiraku Tsujimoto; Yuki Kataoka
Journal:  Cochrane Database Syst Rev       Date:  2021-10-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.